CAV3 Gene Limb-girdle muscular dystrophy autosomal dominant type 1C Genetic Test
Test Details
The CAV3 gene is associated with Limb-girdle muscular dystrophy, autosomal dominant type 1C (LGMD1C). This is a genetic disorder characterized by progressive muscle weakness and wasting primarily affecting the muscles of the hips and shoulders.
NGS (Next-Generation Sequencing) genetic testing is a type of genetic test that allows for the simultaneous analysis of multiple genes, including the CAV3 gene, to identify potential genetic variants or mutations associated with a specific condition. This type of testing is more comprehensive and can provide more detailed information compared to traditional genetic testing methods.
By performing an NGS genetic test for LGMD1C, healthcare providers can identify specific mutations or variants in the CAV3 gene that may be causing the condition. This information can be used for accurate diagnosis, genetic counseling, and potentially targeted treatment options.
It is important to note that genetic testing for LGMD1C should be performed by a qualified healthcare professional, such as a geneticist or genetic counselor, who can interpret the results and provide appropriate guidance and support.
Test Name: CAV3 Gene Limb-girdle muscular dystrophy autosomal dominant type 1C Genetic Test
Components
- Price: 4400.0 AED
- Sample Condition: Blood or Extracted DNA or One drop Blood on FTA Card
- Report Delivery: 3 to 4 Weeks
- Method: NGS Technology
- Test type: Neurological Disorders
- Doctor: Neurologist
- Test Department: Genetics
Pre Test Information
Clinical History of Patient who is going for CAV3 Gene Limb-girdle muscular dystrophy, autosomal dominant type 1C NGS Genetic DNA Test
A Genetic Counselling session to draw a pedigree chart of family members affected with CAV3 Gene Limb-girdle muscular dystrophy, autosomal dominant type 1C
| Test Name | CAV3 Gene Limb-girdle muscular dystrophy autosomal dominant type 1C Genetic Test |
|---|---|
| Components | |
| Price | 4400.0 AED |
| Sample Condition | Blood or Extracted DNA or One drop Blood on FTA Card o |
| Report Delivery | 3 to 4 Weeks |
| Method | NGS Technology |
| Test type | Neurological Disorders |
| Doctor | Neurologist |
| Test Department: | Genetics |
| Pre Test Information | Clinical History of Patient who is going for CAV3 Gene Limb-girdle muscular dystrophy, autosomal dominant type 1C NGS Genetic DNA Test A Genetic Counselling session to draw a pedigree chart of family members affected with CAV3 Gene Limb-girdle muscular dystrophy, autosomal dominant type 1C |
| Test Details | The CAV3 gene is associated with Limb-girdle muscular dystrophy, autosomal dominant type 1C (LGMD1C). This is a genetic disorder characterized by progressive muscle weakness and wasting primarily affecting the muscles of the hips and shoulders. NGS (Next-Generation Sequencing) genetic testing is a type of genetic test that allows for the simultaneous analysis of multiple genes, including the CAV3 gene, to identify potential genetic variants or mutations associated with a specific condition. This type of testing is more comprehensive and can provide more detailed information compared to traditional genetic testing methods. By performing an NGS genetic test for LGMD1C, healthcare providers can identify specific mutations or variants in the CAV3 gene that may be causing the condition. This information can be used for accurate diagnosis, genetic counseling, and potentially targeted treatment options. It is important to note that genetic testing for LGMD1C should be performed by a qualified healthcare professional, such as a geneticist or genetic counselor, who can interpret the results and provide appropriate guidance and support. |
